Conjugation Experiments General Remarks
Conjugation experiments were carried out in standard polypropylene micro test tubes 3810x at atmospheric pressure with mixing at 20 °C unless otherwise stated. Reagents and solvents were purchased from commercial sources and used as supplied. All buffer solutions were prepared with double-deionised water and filter-sterilised. Borate-buffered saline (BBS) was 25 mM sodium borate, 25 mM sodium chloride and 1 mM EDTA at pH 8.0. Phosphatebuffered saline (PBS) was 140 mM sodium chloride and 12 mM sodium phosphates at pH 7.4. Phosphate-buffered saline for SEC-HPLC was 140 mM NaCl, 100 mM sodium phosphates and 0.02% sodium azide at pH 7.0. Ultrapure DMF was purchased from SigmaAldrich and kept under dry conditions. Solutions of tris(2-carboxyethyl)phosphine hydrochloride (TCEP) 10 mM (2.87 mg/mL) were prepared in BBS. Solutions of dehydroascorbic acid (dhAA) 10 mM (1.74 mg/mL) were prepared in PBS. Filtration of particulates was carried out through Spin-X 0.22 µm cellulose acetate filters. Ultrafiltration was carried out in vivaspin 500 polyethersulfone (PES) membrane concentrators with a molecular weight cut-off (MWCO) of 10 kDa or 5 kDa. Centrifugation was carried out on an eppendorf 5415R fixed angle rotor centrifuge operating at 14000 rcf at 20 °C.
Thio-trastuzumab antibody is a trastuzumab (IgG1) variant with an engineered cysteine on each light chain (LC-V205C), directed against HER2. This THIOMAB™ antibody was obtained as a 3.67 mg/mL solution in 50 mM Tris acetates solution (Genentech). Thio-trastuzumab was buffer exchanged into BBS via ultrafiltration (10 kDa MWCO). Concentration was determined by UV-vis absorbance (using ɛ 280 = 210896 M -1 cm -1 or A = 1.422 for 1 mg/mL for thio-trastuzumab), adjusted to 40 μM (5.93 mg/mL) and was stored in aliquots at 4 °C or used for experiments. Thio-trastuzumab drug conjugate (TDC) concentration was determined using the same extinction coefficient as for unmodified thio-trastuzumab (both MMAE and maleamic acid compounds were found to have negligible absorption at 280 nm).
The following acronyms are used to describe light chain (LC) and heavy chain (HC).
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Analytical methods for antibody-drug conjugates SDS-PAGE
Non-reducing glycine-SDS-PAGE 12% acrylamide gels were performed following standard lab procedures. A 4% stacking gel was used and a broad-range MW marker (10-250 kDa, BioLabs) was co-run to estimate protein weights. Samples (3 μL at ~25-30 μM in total thiotrastuzumab) were quenched with maleimide (1 μL of a 10 mM solution in PBS, >110 eq.)
and mixed with loading buffer (2 μL, composition for 6× SDS: 1 g SDS, 3 mL glycerol, 6 mL 0.5 M Tris buffer pH 6.8, 2 mg R-250 dye) and heated at 65 °C for 2 minutes. For reducing gel (using β-mercaptoethanol (BME) as reducing agent), samples (3 μL at ~25-30 μM in total thio-trastuzumab) were mixed with loading buffer (2 μL, composition for 4 x SDS: 0.8 mL BME, 0.8 g SDS, 4 mL glycerol, 2.5 mL 0.5 M Tris buffer pH 6.8, 2.5 mL H 2 O, 2 mg R-250 dye).
The gel was run at constant current (30-35 mA) for 40 min in 1× SDS running buffer. All gels were stained following a modified literature protocol 1 where 0.12 % of Coomassie G-250 and
Coomassie R-250 dyes were added to the staining solution (5:4:1 MeOH:H 2 O:AcOH).
Determination of thio-trastuzumab and conjugate concentration
UV-vis spectra were recorded on a Varian Cary 100 Bio UV-visible spectrophotometer, operating at 20 °C using a cell length (l) of 1 cm. Sample buffer was used as blank for baseline correction. Calculation of antibody concentration follows the Beer-Lambert law using ɛ 280 = 210896 M -1 cm -1 for thio-trastuzumab. Thio-trastuzumab drug conjugate (TDC) 3 concentration was calculated as follows using the same extinction coefficient for thiotrastuzumab since the maleamic acid group and MMAE were found to have negligible absorption at 280 nm compared to thio-trastuzumab. Thio-trastuzumab fluorophore conjugate (TFC) 5 concentration was calculated using the same extinction coefficient for thio-trastuzumab, applied to a corrected absorption value at 280 nm calculated as follows by 
Liquid chromatography mass spectrometry (LC-MS)
Thio-trastuzumab and TDC 3 samples were prepared in water (6.6 μM, 1 mg/mL). LC-MS analysis was performed on a Hypersil Gold C4 1.9 μm 2.1 × 50 mm column connected to an 
Size-exclusion chromatography (SEC)
Thio-trastuzumab and TDC 3 were prepared as 13 μM (2 mg/mL) solutions in PBS. Samples were analysed by SEC-HPLC on a TSK gel G3000SWXL (7.8 mm x 30 cm) column connected to an Agilent 1100 HPLC system equipped with a 1100 series diode array detector. Samples were eluted using PBS 100 mM NaCl, 50 mM sodium phosphates and 0.02% sodium azide at pH 7.0 as mobile phase at a flow rate of 0.5 mL/ min. over 30 min. Detection wavelength was 280 nm.
Enzyme-linked immunosorbent assay (ELISA)
Binding affinity to HER2 receptor was determined by ELISA. PBS 140 mM sodium chloride and 12 mM sodium phosphates at pH 7.4 was used for all solutions. A maxisorp 96-well plate was coated for 2 h at 20 °C with HER2 (100 μL of a 0.25 μg/mL solution in PBS). One row of wells was coated with PBS only as a negative control. Next, each well was washed with PBS and blocked with a 3% BSA solution in PBS (200 μL) overnight at 4 °C. Then, the wells were washed with 0.1% Tween 20 in PBS, followed by PBS. Thio-trastuzumab and TDC 3 were diluted in PBS yielding the following concentrations (nM): 80, 60, 40, 20, 10, 5, 2.5, 1.25, 0. 42, and 0.14 nM. The dilution series was added, including PBS only and thio-trastuzumab or TDC 3 at 80 nM in the absence of HER2 as negative controls. The plate was incubated for 2 h at 20 °C. Then, wells were washed and the detection antibody (100 μL of anti-human IgG, Fab-specific-HRP solution, 1:5000 in PBS) was added followed by incubation for 1 h at 20 °C.
After another washing step, freshly prepared OPD solution (100 μL of 10 mg/20 mL OPD in phosphate-citrate buffer) was added to each well and the reaction was stopped by addition of 4 M HCl (50 μL). The colorimetric reaction was measured at 490 nm. Absorption values for a given concentration of thio-trastuzumab or TDC 3 were corrected as follows, where A 490corr is corrected absorption, A 490corr is measured absorption, A PBS is absorption for PBS control, A TmAb80 is absorption for thio-trastuzumab or TDC 3 control at 80 nM and C is the given concentration for the respective data point. were analysed by SEC-HPLC on a TSK gel G3000SWXL (7.8 mm x 30 cm) column connected to an Agilent 1200 HPLC system equipped with a 1200 series diode array detector and a fluorescence detector. Samples were eluted using PBS 140 mM NaCl, 100 mM sodium phosphates and 0.02% sodium azide at pH 7.0 as mobile phase at a flow rate of 0.5 mL/ min. over 30 min. Fluorescence was detected with an excitation wavelength of 495 nm and emission wavelength of 525 nm.
Determination of drug to antibody ratio (DAR)
To TDC 3 (20 μM, 50 μL, 0.001 μmol) in BBS pH 8 was added TCEP (2 mM, 5 μL, 10 eq.) and the reaction was incubated at 37 °C for 3 h under mild agitation (400 rpm). Then, added maleimide (10 mM, 10 μL, 100 eq.) Purified by ultrafiltration (10 kDa MWCO) into water and immediately analysed by LC-MS as described above. Total protein mass spectra were obtained from reconstructed ion series. Light chain (LC) species peaks were integrated to determine number of counts per mass species. The drug to antibody ratio (DAR) was calculated as follows, where LC-MMAE nonHyd is number of counts for light chain species (only proton adduct was observed) modified with one maleimide PEG 12 -vc-PABC-MMAE payload and one maleimide, LC−MMAE Hyd is number of counts for light chain species (proton and sodium adducts) modified with one maleamic PEG 12 -vc-PABC-MMAE payload and one maleimide, and LC−Mal is number of counts for light chain species modified with two maleimides alone (only proton adduct was observed).
Determination of fluorophore to antibody ratio (FAR)
UV-vis spectra were recorded on a Varian Cary 100 Bio UV-visible spectrophotometer, operating at 20 °C. Sample buffer was used as blank for baseline correction. 
Cell Lines
Three human breast cancer cell lines SKBR-3 (Her-2-positive), HCC-1954 (Her-2-positive) and MCF-7 (Her-2-negative) were purchased from ATCC, and maintained in McCoy's 5A, RPMI-1640, and DMEM medium, respectively, all supplemented with 10% foetal bovine serum (Life Technologies, UK) at 37 °C, 5% CO 2 .
In Vitro Cytotoxicity Assessment
In vitro cytotoxicity of the compounds was evaluated in all three human breast cancer cell lines (SKBR-3, HCC-1954 and MCF-7) by the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] colourimetric assay. Briefly, 5×10 4 cells were seeded in 96-well plates and incubated overnight. Cells were then exposed to a range of concentrations (0-100 nM) of MMAE (24h), thio-trastuzumab (72h) and TDC 3 (72h).
Following each treatment, cells were washed with PBS and incubated with drug-free medium for five days. The MTT reagent (5 mg/ml) was then added to each well and cells were incubated for 2h, followed by the addition of ethanol:DMSO (1:1) solution and optical density (OD) was measured at 540 nm. The percentage of viable cells was calculated as follows:
Conjugation protocols
Conjugation of thio-trastuzumab with MBM 1 (conjugate TDC 3)
To thio-trastuzumab (40 μM, 200 μL, 0.008 μmol) in BBS pH 8 was added TCEP (10 mM, 8 μL, 10 eq.) and the reaction was incubated at 37 °C for 3 h under mild agitation (400 rpm). The buffer was exchanged to PBS 140 mM sodium chloride and 12 mM sodium phosphates at To thio-trastuzumab (40 μM, 80 μL, 0.0032 μmol) in BBS pH 8 was added TCEP (10 mM, 3.2 μL, 10 eq.) and the reaction was incubated at 37 °C for 3 h under mild agitation (400 rpm). The buffer was exchanged to PBS 140 mM sodium chloride and 12 mM sodium phosphates at pH 7.4 by ultrafiltration (5 kDa MWCO) to remove unreacted TCEP and the volume was corrected to 80 μL. Next, added dhAA (10 mM, 6.4 μL, 20 eq.) and the reaction was incubated at 37 °C for 3 h under mild agitation (400 rpm). The buffer was exchanged to BBS pH 8 by ultrafiltration (5 kDa MWCO) to remove unreacted dhAA and the volume was corrected to 80 μL. Then, MBM 2 was prepared in dry DMF (10 mM, 1.3 μL, 4 eq.) and added to the thio-trastuzumab solution. The reaction was incubated at 20 °C for 4 h. Afterwards, excess reagents were removed by ultrafiltration (5 kDa MWCO) with 50 mM phosphate buffer at pH 7.0 and the volume corrected to 80 µL to afford the modified thio-trastuzumab conjugate TAC 4 in PBS. Next, added tris(3-hydroxypropyltriazolylmethyl)amine (THPTA, S10 DMF (5 mM, 6.4 µL, 10 eq.), followed by sodium ascorbate (final concentration 5 mM) and the reaction mixture was incubated at 20 °C for 1 h. Excess reagents were removed by ultrafiltration (5 kDa MWCO) into fresh PBS to afford the modified thio-trastuzumab conjugate TFC 5 with 40% yield and a fluorophore to thio-trastuzumab ratio of 1.1.
Conjugation of albumin with MBM 2, followed by copper-catalysed Huisgen 1,3-dipolar cycloaddition (CuAAC) with Alexa Fluor 488® (used as control for serum stability study)
To albumin (40 μM, 300 μL, 0.012 μmol) in BBS pH 8 was added dithiothreitol (DTT 10 mM, 6 μL, 5 eq.) and the reaction was incubated at 20 °C for 90 min. under mild agitation (400 rpm). The buffer was exchanged to fresh BBS pH 8 by ultrafiltration (5 kDa MWCO) to remove unreacted DTT and the volume was corrected to 300 μL. In a separate vial, MBM 2 was prepared in dry DMF (10 mM, 6 μL, 5 eq.) and added tris(3-hydroxypopyltriazolylmethyl)amine (THPTA, 50 mM, 2.4 µL, 10 eq.) and CuSO 4 (20 mM, 6 µL, 10 eq.). Next, added Alexa Fluor 488® in DMF (5 mM, 18 µL, 7.5 eq.), followed by sodium ascorbate (final concentration 5 mM) in 50 mM phosphate buffer pH 7. This reaction mixture was incubated at 20 °C for 4 h. Then, it was added to the reduced albumin solution and the mixture was incubated at 20 °C for 1 h. Afterwards, excess reagents were removed by ultrafiltration (5 kDa MWCO) with 50 mM phosphate buffer at pH 7.0 and the volume corrected to 300 µL to afford the modified albumin conjugate in PBS with 76% yield and a fluorophore to albumin ratio of 1.0. 
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Synthesis of compounds
Scheme S1 -Synthesis of MBMs 1 and 2.
2-(3-bromo-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)acetic acid 6 (MBM 6)
In a 10 mL round-bottom flask, suspended 3-bromomaleic anhydride (186 μL, 354 mg, 2 mmol) and glycine (150 mg, 2 mmol, 1 eq.) in acetic acid (2 mL 
BocHN-vc-PABC-MMAE 7
This protocol is a modification of a literature protocol 2 . In a 10 mL round-bottom flask, suspended BocHN-vc-PABC-PNP (31 mg, 48 µmol, 1.6 eq.), and 1-hydroxybenzotriazole hydrate (HOBt, 12 mg, 90 µmol, 3 eq.) in DMF (0.2 mL). Next, dissolved monomethyl auristatin E (MMAE, 25 mg, 30 µmol, 1 eq.) in MeCN (0.8 mL) and added to the reaction mixture. Then, added DIPEA (52 µL, 300 µmol, 10 eq.). The solution turned yellow over time.
The solution was stirred at 20 °C over 16 hours. Then, added DCM (10 mL) and washed with aq. sat. NaHCO 3 (3×10 mL), 0.1 M aq. acetates pH 5 (10 mL) and 1:1 water:sat. LiCl (10 mL).
The organic layer was dried (MgSO 4 ), filtered and concentrated under vacuum to yield an off-white solid which was purified by preparative liquid chromatography on silica with a gradient of DCM:EtOAc:MeOH (5:5:2 to 10:3:1 v/v) to afford the title compound as a white solid (21 mg, 17 μmol, 57%). 
BocHN-vc-PABC-propargylamide 8
In a 10 mL round-bottom flask, BocHN-vc-PABC-PNP (129 mg, 0.2 mmol, 1 eq.) was dissolved in DMF (2 mL). Next, added HOBt hydrate (54 mg, 0.4 mmol, 2 eq.), followed by addition of propargylamine (13 µL 
BocHN-PEG 12 -vc-PABC-MMAE 9
In a 10 mL round-bottom flask, dissolved BocHN-vc-PABC-MMAE 7 (34 mg, 28 µmol, 1 eq.) in dry DCM (0.9 mL) and added trifluoroacetic acid (TFA, 0.1 mL). Stirred at 20 °C over 2 hours. chromatogram of TFC 5 incubated in blood serum for 0 days (blue), 1 day (red), 2 days (green), 4 days (pink), 7 days (beige) and 10 days (purple). All chromatograms are normalised to the antibody fraction.
